Claims

1. The use of a dose of at least 10^8 $TCID_{50}$ (50% Tissue Culture Infective Dose) of an Modified Vaccinia virus Ankara (MVA) for the manufacture of a pharmaceutical composition for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in the human neonate or infant prior to 6 months of age in the absence of a second dose of the MVA.

2. The use of claim 1, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in a human infant of less than 2 months of age.

3. The use of claim 1, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in a human neonate.

4. The use of claim 1, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in a human neonate within 72 hours after birth.

5. The use of claim 1, the pharmaceutical composition being for inducing protective T- and B-cell responses against an orthopoxvirus.

6. The use of claim 1, the pharmaceutical composition being for inducing protective T- and B-cell responses against a Vaccinia virus.

7. The use of claim 1, the pharmaceutical composition being for inducing protective T- and B-cell responses against smallpox.

8. The use of claim 1, wherein the MVA is a recombinant MVA.

9. The use of claim 8, the pharmaceutical composition being for inducing T- and B-cell responses against a heterologous antigen encoded by the recombinant MVA.

10. The use of a dose of at least 10^8 $TCID_{50}$ (50% Tissue Culture Infective Dose) of an Modified Vaccinia virus Ankara (MVA) for the manufacture of a pharmaceutical

composition for inducing a protective immune response against a poxvirus in a human neonate or infant of less than 6 months of age, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in the human neonate or infant within 2 weeks of the dose of the MVA.

11. The use of claim 10, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in a human infant of less than 2 months of age.

12. The use of claim 10, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in a human neonate.

13. The use of claim 10, the pharmaceutical composition being for inducing protective T- and B-cell responses against a poxvirus in a human neonate within 72 hours after birth.

14. The use of claim 10, the pharmaceutical composition being for inducing protective T- and B-cell responses against an orthopoxvirus.

15. The use of claim 10, the pharmaceutical composition being for protective T- and B-cell responses against a Vaccinia virus.

16. The use of claim 10, the pharmaceutical composition being for inducing protective T- and B-cell responses against smallpox.

17. The use of claim 10, wherein the MVA is a recombinant MVA.

18. The use of claim 17, the pharmaceutical composition being for inducing T- and B-cell responses against a heterologous antigen encoded by the recombinant MVA.